行情

HZNP

HZNP

Horizon Therapeutics Plc
NASDAQ

实时行情|Nasdaq Last Sale

76.06
+3.84
+5.32%
盘后: 78.90 +2.84 +3.73% 18:11 08/07 EDT
开盘
71.79
昨收
72.22
最高
78.93
最低
71.60
成交量
1,151.47万
成交额
--
52周最高
77.45
52周最低
23.81
市值
145.11亿
市盈率(TTM)
31.08
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测HZNP价格均价为87.40,最高价位123.00,最低价为42.00。

EPS

HZNP 新闻

更多
Horizon Therapeutics prices 11.8M-share offering
Horizon Therapeutics (NASDAQ:HZNP) has priced its public offering of 11.8M ordinary shares at $71.00/share, for expected net proceeds of ~$798.9M. Underwri
seekingalpha · 1天前
Horizon Therapeutics Named 2020 Top Workplace for Millennials by Fortune
Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named to the 2020 Fortune Best Workplaces for Millennials™ list. Horizon ranked 7th among 25 companies in the small and medium company category in its first year on the list.
Business Wire · 2天前
Horizon Therapeutics plc Announces Proposed Public Offering of Ordinary Shares
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it is offering to sell $700,000,000 of its ordinary shares in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional $105,
Business Wire · 3天前
Why Horizon Therapeutics Stock Is Up Today
Shares of Horizon Therapeutics (NASDAQ: HZNP) are up by 17% as of 11:54 a.m. EDT on Wednesday, after the company reported better-than-expected second-quarter financial results before the market opened today. During the second quarter, Horizon Therapeutics' ne
Motley Fool · 3天前
Recap: Horizon Therapeutics Q2 Earnings
Shares of Horizon Therapeutics (NASDAQ:HZNP) were unchanged after the company reported Q2 results.Quarterly Results Earnings per share fell 18.37% over the past year to $0.40, which beat the estimate of $0.34.Revenue of $462,779,000 up by 44.33% from the same
Benzinga · 3天前
Horizon Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also raised its FY20 sales guidance above analyst estimates.
Benzinga · 3天前
Horizon Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also raised its FY20 sales guidance above analyst estimates.
Benzinga · 3天前
Horizon Therapeutics Raises FY20 Sales Guidance From $1.40B-$1.45B To $1.85B-$1.90B vs $1.54B Est.
Benzinga · 3天前

所属板块

制药
+0.19%
制药与医学研究
+0.08%

热门股票

代码
价格
涨跌幅

HZNP 简况

Horizon Therapeutics plc(原名:Horizon Pharma plc)是一家罕见疾病的生物制药公司。该公司致力于研究、开发并商业化满足罕见病及风湿性疾病患者需求的药物。该公司销售约10种药物,其中6种用于罕见病和风湿性疾病。该公司的上市药物包括ACTIMMUNE(干扰素γ-1b)、BUPHENYL(苯基丁酸钠)片剂与粉剂、DUEXIS(布洛芬/法莫替丁)、KRYSTEXXA(聚乙二醇脱唾液酸酶)、PENNSAID(双氯芬酸钠局部溶液)2% w/w或PENNSAID 2%、PROCYSBI(半胱胺酒石酸氢盐)缓释胶囊、QUINSAIR(左氧氟沙星喷雾)、RAVICTI(甘油苯基丁酸酯)口服液、RAYOS(泼尼松)缓释片和VIMOVO(萘普生/艾美拉唑镁)。
展开

微牛提供Horizon Therapeutics PLC(NASDAQ-HZNP)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的HZNP股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易HZNP股票基本功能。